Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase.
Stancovski
I
I
Weizmann Institute of Science, Rehovot, Israel.
Sela
M
M
Yarden
Y
Y
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000918:Antibody Specificity; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy; D009374:Neoplasms, Experimental / Q000235:genetics* / Q000628:therapy; D011379:Prognosis; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics / Q000502:physiology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000502:physiology*
D000911:Antibodies, Monoclonal; D020794:Receptor Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases